Novel drugs selectively target pathway important in rheumatoid arthritis
Wednesday, January 14, 2009 - 04:35
in Health & Medicine
Methotrexate (MTX), a folate antagonist that blocks folic acid activity, is the most widely used disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. It enters the cell via several pathways, one of which involves folate receptor beta (FRbeta), which is highly specific for cells present in the joints of patients with rheumatoid arthritis (RA)...
Read the whole article on Science Centric
More from Science Centric
Related
- Novel drugs selectively target pathway important in rheumatoid arthritisTue, 13 Jan 2009, 16:57:27 EST
- Medicaid policies vary widely for rheumatoid arthritis drugsTue, 4 Nov 2008, 13:35:58 EST
- New guidelines for treating rheumatoid arthritisTue, 22 Jul 2008, 14:07:20 EDT
- Cost shifting may make arthritis medications too expensive for medicare beneficiariesMon, 1 Jun 2009, 19:22:40 EDT
- Wide variability in rheumatoid arthritis drug suggests alternative dosing should be consideredTue, 4 Nov 2008, 13:35:52 EST